Trimethoprim and Rifampicin: In Vitro Activities Separately and in Combination
Rifampicin (rif) and trimethoprim (tm) are familiar broad-spectrum oral antimicrobial agents. Both drugs owe their antibacterial activity primarily to their effect on the biosynthesis of nucleic acids. Their target sites may thus be regarded as occurring on the same metabolic pathway; sequential blockade of a metabolic pathway has been shown to result in a potentially synergistic situation. Consequently, we tested rif and tm in combination, to investigate possible antibacterial interactions.
KeywordsBacteroides Fragilis Royal Free Hospital Klebsiella Aerogenes Streptococcal Strain Pathogenic Bacterial Species
Unable to display preview. Download preview PDF.
- Brumfitt, W., Faiers, M.C., Pursell, R.E., Reeves, D.S. Turnbull, A.R. 1969 Postgrad.Med.J. Suppl. 45, 56.Google Scholar
- Elion, G.V., Singer, S. Hitchings, C.H. 1954 J.Biol.Chem., 208, 477.Google Scholar
- Kerry, D.W., Hamilton-Miller, J.M.T. Brumfitt, W. 1975 J. Antimicrob.Chemotherapy. In press.Google Scholar
- Reisberg, B., Hertzog, J. Weinstein, L. 1967 Antimicrob. Agents Chemotherapy-1966, 424.Google Scholar
- Sabath, L.D. 1968 Antimicrob. Agents Chemotherapy-1967, 210.Google Scholar